Aptevo Therapeutics Inc. annual report, FY2016

Business context and reporting period

Aptevo Therapeutics Inc. is a biotechnology company with four marketed hematology and infectious-disease products and an oncology and hematology pipeline based largely on its ADAPTIR platform. This Form 10-K covers the fiscal year ended December 31, 2016; Aptevo became independent through its spin-off from Emergent BioSolutions on August 1, 2016. Pre-spin-off results are carve-out financials and may not reflect costs as a standalone company. The filing restates 2015 audited financial statements and certain 2016 quarterly information.

Financial results and liquidity

• Product sales rose 30%, led by IXINITY, whose sales increased to $9.8 million from $1.0 million, and VARIZIG, up to $3.4 million from $2.3 million. HepaGam B sales declined to $8.6 million from $10.3 million; WinRho sales were $14.4 million versus $14.2 million.
• Total revenue increased modestly despite collaborations revenue falling to $0.2 million from $5.7 million, primarily because FY 2015 included a $5.0 million MorphoSys milestone payment.
• Gross margin contracted to 34% from 50%. Aptevo expensed $7.1 million of unsuccessful IXINITY manufacturing costs in 2016.
• The $112.4 million net loss includes a $71.0 million noncash impairment: $41.8 million for otlertuzumab in-process R&D and $29.2 million of goodwill. A $15.3 million income-tax benefit partly offset the loss.
• At year-end, cash and cash equivalents were $9.7 million, short-term investments $44.8 million, and restricted cash $0.4 million. The filing separately reports liquidity of $54.9 million; the balance-sheet components total approximately $54.9 million including restricted cash.
• Debt: Aptevo drew $20.0 million under a $35.0 million MidCap facility; reported long-term debt, net, was $18.4 million. A further $15.0 million tranche was conditional on revenue and receipt of Emergent funding. Emergent paid the separate $20.0 million promissory note in January 2017.

Material changes, outlook and risks

• Management said available cash, investments and facility proceeds were expected to fund operations for at least 12 months; it also stated existing cash and equivalents were expected to support operations through the first quarter of 2018. The company expected operating losses and negative operating cash flows for the foreseeable future and said additional funding would be needed to complete clinical development. No specific revenue or earnings guidance was provided.
• IXINITY supply was disrupted by manufacturing failures: none of five bulk-drug batches ordered in 2016 met release specifications. Aptevo reported a successful batch in March 2017 and expected supply to resume in May 2017, subject to final manufacturing. Lower supply could reduce sales and jeopardize credit-facility revenue covenants.
• MOR209/ES414’s Phase 1 trial was amended to continuous infusion after most patients on weekly dosing developed anti-drug antibodies that reduced drug concentration and could affect efficacy. The amended trial began in December 2016. MorphoSys had a one-time termination right through June 30, 2017 or following review of data from the first six patients; cost-sharing terms also change over time.
• The company relies on Emergent for hyperimmune-product manufacturing and logistics, and on third parties for IXINITY production and fill-finish. Replacing sole-source suppliers could require significant time, expense and regulatory approvals.
• In 2016, Aptevo restated 2015 and specified 2016 interim financial information after identifying an omitted deferred-tax liability related to acquired in-process R&D. Management identified a material weakness in deferred-tax controls through September 30, 2016, reported remediation actions, and concluded the weakness was sufficiently remediated. The auditor did not express an opinion on internal-control effectiveness.
• Other material risks include ongoing losses and financing needs, competition and reimbursement pressure, clinical and regulatory uncertainty, potential adverse events, patent disputes, and restrictions or indemnification exposure under the tax matters agreement with Emergent.
• Otlertuzumab plus bendamustine showed a higher response rate (69% versus 39%) and longer median progression-free survival (15.9 versus 10.1 months) than bendamustine alone in a Phase 2 study; these are clinical findings, not approved-use or revenue outcomes.

Key facts for investors to verify

• IXINITY manufacturing recovery, inventory availability, sales trajectory and compliance with MidCap revenue covenants.
• Cash burn, facility availability and the timing and terms of any additional financing.
• MOR209/ES414 data from the first six patients under the amended protocol and whether MorphoSys continues the collaboration.
• Progress and commercial prospects for the marketed products and pipeline, including otlertuzumab’s development path after the impairment.
• Whether deferred-tax control remediation remains effective and whether any further restatements or control issues arise.
• The filing’s Business section cites 2015 R&D expense of $37.4 million, whereas its audited statements and MD&A table report $34.7 million; verify the intended comparable figure.